Most Recent Articles by Bryant Furlow
Extramedullary multiple myeloma is increasingly encountered in the clinic and most patients will need aggressive treatment.
CDK4/6 Inhibitors in Breast Cancer Treatment: Recent Research, Safety Profiles, Acquired Resistance, Next StepsSep 11, 2017
Breast tumors can become resistant to CDK 4/6 inhibitors, but improved understanding of the mechanisms of acquired resistance might point to additional treatment strategies.
Durvalumab's optimal clinical role in managing lung cancer remains unclear and more robust predictive biomarkers are needed.
CT-P10 and GP2013 exhibit non-inferior overall response efficacy and equivalent pharmacokinetics to rituximab among patients with advanced follicular lymphoma.
Relapse is inevitable in mantle cell lymphoma. Treatment of relapsed MCL is, however, evolving, with several treatment regimen options, though ibrutinib is still the standard of care.
More Articles by Bryant Furlow
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- beta-Carotene and Cancer
- Novel Therapeutic Target in Chronic Lymphocytic Leukemia Cells Identified
- Venetoclax Plus Rituximab May Prolong Progression-free Survival in CLL
- Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer
- Different Types of Obesity May Increase Risk of Breast Cancer Subtypes